Syntara Ltd (ASX:SNT) CEO Gary Phillips tells Proactive the company has dosed the first patient in a phase two clinical trial assessing its pan-LOX inhibitor SNT-5505 in combination with kinase inhibitor ruxolitinib in patients with bone marrow cancer myelofibrosis. The first phase of trials demonstrated an “excellent safety profile and encouraging signs of efficacy when used in patients who had failed on current standard of care.” The company expects to complete recruitment for this cohort of patients in the first half of 2024. Syntara recently showcased data from the first cohort of MF-101 where SNT-5505 was used for six months in patients as a monotherapy at the American Society of Hematology’s (ASH) annual meeting in San Diego.
Syntara doses first patient in phase 2 blood cancer study
